Cecilia M. Shikuma to Anti-HIV Agents
This is a "connection" page, showing publications Cecilia M. Shikuma has written about Anti-HIV Agents.
Connection Strength
5.692
-
Gangcuangco LMA, Mitchell BI, Siriwardhana C, Kohorn LB, Chew GM, Bowler S, Kallianpur KJ, Chow DC, Ndhlovu LC, Gerschenson M, Shikuma CM. Mitochondrial oxidative phosphorylation in peripheral blood mononuclear cells is decreased in chronic HIV and correlates with immune dysregulation. PLoS One. 2020; 15(4):e0231761.
Score: 0.535
-
D'Antoni ML, Paul RH, Mitchell BI, Kohorn L, Fischer L, Lefebvre E, Seyedkazemi S, Nakamoto BK, Walker M, Kallianpur KJ, Ogata-Arakaki D, Ndhlovu LC, Shikuma C. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism. J Acquir Immune Defic Syndr. 2018 09 01; 79(1):108-116.
Score: 0.477
-
Riangwiwat T, Kohorn LB, Chow DC, Souza SA, Ndhlovu LC, Wong JW, Gangcuangco LM, Shikuma CM. CD4/CD8 Ratio Predicts Peripheral Fat in HIV-Infected Population. J Acquir Immune Defic Syndr. 2016 May 01; 72(1):e17-9.
Score: 0.406
-
Mitchell BI, Byron MM, Ng RC, Chow DC, Ndhlovu LC, Shikuma CM. Elevation of Non-Classical (CD14+/lowCD16++) Monocytes Is Associated with Increased Albuminuria and Urine TGF-?1 in HIV-Infected Individuals on Stable Antiretroviral Therapy. PLoS One. 2016; 11(4):e0153758.
Score: 0.405
-
Chow D, Kohorn L, Souza S, Ndhlovu L, Ando A, Kallianpur KJ, Byron MM, Baumer Y, Keating S, Shikuma C. Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin. AIDS. 2016 Feb 20; 30(4):672-4.
Score: 0.400
-
Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014 Dec; 20(6):571-82.
Score: 0.363
-
Shikuma C, Gerschenson M, Ananworanich J, Valcour V, Teeratakulpisarn N, Jadwattanakul T, Degruttola V, Liang CY, McArthur J, Ebenezer G, Chomchey N, Praihirunkit P, Hongchookiath P, Mathajittiphun P, Nakamoto B, Hauer P, Phanuphak P, Phanuphak N. Determinants of epidermal nerve fibre density in antiretroviral-na?ve HIV-infected individuals. HIV Med. 2012 Nov; 13(10):602-8.
Score: 0.308
-
Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011 May; 27(5):461-8.
Score: 0.278
-
Nakamoto BK, McMurtray A, Davis J, Valcour V, Watters MR, Shiramizu B, Chow DC, Kallianpur K, Shikuma CM. Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):759-65.
Score: 0.271
-
Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):540-50.
Score: 0.217
-
Chow DC, Day LJ, Souza SA, Shikuma CM. Metabolic complications of HIV therapy. IAPAC Mon. 2006 Sep; 12(9):302-17.
Score: 0.208
-
Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, Evans S, Mulligan K. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis. 2004 Oct 15; 39(8):1223-30.
Score: 0.182
-
Shikuma CM, Kohorn L, Paul R, Chow DC, Kallianpur KJ, Walker M, Souza S, Gangcuangco LMA, Nakamoto BK, Pien FD, Duerler T, Castro L, Nagamine L, Soll B. Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy. HIV Clin Trials. 2018 08; 19(4):139-147.
Score: 0.121
-
Zungsontiporn N, Ndhlovu LC, Mitchell BI, Stein JH, Kallianpur KJ, Nakamoto B, Keating SM, Norris PJ, Souza SA, Shikuma CM, Chow DC. Serum amyloid P (SAP) is associated with impaired brachial artery flow-mediated dilation in chronically HIV-1 infected adults on stable antiretroviral therapy. HIV Clin Trials. 2015 11; 16(6):228-35.
Score: 0.098
-
Thao VP, Quang VM, Wolbers M, Anh ND, Shikuma C, Farrar J, Dunstan S, Chau NVV, Day J, Thwaites G, Le T. Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam. Medicine (Baltimore). 2015 Oct; 94(43):e1715.
Score: 0.097
-
Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl DA, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Jacobson DL. Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr. 2015 Jan 01; 68(1):73-80.
Score: 0.092
-
O-charoen P, Ndhlovu LC, Gangcuangco LM, Keating SM, Norris PJ, Ng RC, Mitchell BI, Shikuma CM, Chow DC. Albuminuria is associated with elevated acute phase reactants and proinflammatory markers in HIV-infected patients receiving suppressive combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2014 Dec; 30(12):1185-91.
Score: 0.092
-
Nakamoto BK, Shikuma CM, Ogata-Arakaki D, Umaki T, Neuwelt EA, Shiramizu BT, Chow DC, Parikh NI, Kallianpur KJ, Hamilton BE. Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder. J Neurovirol. 2013 Dec; 19(6):601-5.
Score: 0.085
-
Gangcuangco LM, Chow DC, Liang CY, Nakamoto BK, Umaki TM, Kallianpur KJ, Shikuma CM. Predictors of 25-hydroxyvitamin D levels in HIV-infected patients in Hawai'i. Hawaii J Med Public Health. 2013 Jun; 72(6):197-201.
Score: 0.083
-
Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Tebas P, Campbell TB, Jacobson DL. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):381-9.
Score: 0.080
-
McLinden R, Paris R, Polonis V, Close N, Su Z, Shikuma C, Margolis D, Kim J. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS. 2012 Jul 17; 26(11):1452.
Score: 0.078
-
Nakamoto BK, Jahanshad N, McMurtray A, Kallianpur KJ, Chow DC, Valcour VG, Paul RH, Marotz L, Thompson PM, Shikuma CM. Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals. J Neurovirol. 2012 Aug; 18(4):303-12.
Score: 0.077
-
Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010 Mar; 201(5):662-71.
Score: 0.066
-
Sithinamsuwan P, Punthanamongkol S, Valcour V, Onsanit S, Nidhinandana S, Thitivichianlert S, Shikuma C. Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):456-8.
Score: 0.061
-
Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):193-200.
Score: 0.055
-
Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23.
Score: 0.054
-
Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman KL, Gulick RM. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007 Apr 15; 195(8):1169-76.
Score: 0.054
-
Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006 Aug 16; 296(7):769-81.
Score: 0.052
-
Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther. 2006; 11(6):751-60.
Score: 0.050
-
Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord. 2005 Sep; 5(3):255-62.
Score: 0.048
-
Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001 Sep 28; 15(14):1801-9.
Score: 0.037
-
Bowler S, Mitchell BI, Kallianpur KJ, Chow D, Jiang W, Shikuma CM, Ndhlovu LC. Plasma anti-CD4 IgG is associated with brain abnormalities in people with HIV on antiretroviral therapy. J Neurovirol. 2021 04; 27(2):334-339.
Score: 0.036
-
SahBandar IN, Chew GM, Corley MJ, Pang APS, Tsai N, Hanks N, Khadka VS, Klatt NR, Hensley-McBain T, Somsouk M, Vujkovic-Cvijin I, Chow DC, Shikuma CM, Ndhlovu LC. Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade. AIDS. 2020 08 01; 34(10):1451-1460.
Score: 0.034
-
Gojanovich GS, Shikuma CM, Milne C, Libutti DE, Chow DC, Gerschenson M. Subcutaneous Adipocyte Adenosine Triphosphate Levels in HIV Infected Patients. AIDS Res Hum Retroviruses. 2020 01; 36(1):75-82.
Score: 0.032
-
Premeaux TA, D'Antoni ML, Abdel-Mohsen M, Pillai SK, Kallianpur KJ, Nakamoto BK, Agsalda-Garcia M, Shiramizu B, Shikuma CM, Gissl?n M, Price RW, Valcour V, Ndhlovu LC. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019 04; 25(2):150-161.
Score: 0.030
-
D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 12; 104(6):1241-1252.
Score: 0.030
-
Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, Keating S, Lanteri M, Samuels ML, Hoh R, Sacha JB, Norris PJ, Niki T, Shikuma CM, Hirashima M, Deeks SG, Ndhlovu LC, Pillai SK. Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathog. 2016 06; 12(6):e1005677.
Score: 0.026
-
Hanna DB, Guo M, Bu?kov? P, Miller TL, Post WS, Stein JH, Currier JS, Kronmal RA, Freiberg MS, Bennett SN, Shikuma CM, Anastos K, Li Y, Tracy RP, Hodis HN, Delaney JA, Kaplan RC. HIV Infection and Carotid Artery Intima-media Thickness: Pooled Analyses Across 5 Cohorts of the NHLBI HIV-CVD Collaborative. Clin Infect Dis. 2016 07 15; 63(2):249-56.
Score: 0.025
-
Tongma C, Shikuma CM, Nakamoto BK, Kallianpur KJ, Umaki TM, Barbour JD, Ndhlovu L, Parikh NI, Chow DC. Albuminuria as a marker of cardiovascular risk in HIV-infected individuals receiving stable antiretroviral therapy. Hawaii J Med Public Health. 2013 Sep; 72(9 Suppl 4):34-8.
Score: 0.021
-
Valcour VG, Shikuma CM, Shiramizu BT, Williams AE, Watters MR, Poff PW, Grove JS, Selnes OA, Sacktor NC. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005 Jan 01; 38(1):31-6.
Score: 0.012
-
Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM. A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr. 2003 Mar 01; 32(3):281-6.
Score: 0.010
-
Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002 Sep 27; 16(14):1915-23.
Score: 0.010